
Inherited from Regenxbio
Tern Therapeutics, founded by former Regenxbio leaders Alex Bailey, Christina Ohnsman, and Matthew Rosini, is focused on continuing the work they began at their former company. TTX-381, the most advanced candidate, is an adeno-associated viral (AAV) vector-based gene therapy designed to deliver a copy of the TPP1 gene directly to the retina, aiming to treat vision loss in CLN2 patients. This therapy is currently being evaluated in a Phase I/II clinical trial in the UK, involving up to 16 children aged 1 to 12. The trial is expected to conclude in 2025.
The second candidate, TTX-181, is also an AAV vector-based therapy but is delivered directly to the central nervous system (CNS) to halt neurodegeneration. This therapy showed promise in a 2022 investigator-initiated study in Brazil, where it was well-tolerated in a child with no serious adverse events reported.
Funding and Future Outlook
The $15 million funding round, led by ATW Partners and Steve Oliveira of Nemean Asset Management, is intended to support the ongoing trial of TTX-381 and advance TTX-181 further into development. The leadership at Terns, experienced in gene therapy from their time at Regenxbio, is committed to advancing these therapies, which they believe are crucial for the patient community suffering from rare diseases like CLN2.
As Tern Therapeutics embarks on this journey, the biotech aims to bring these promising therapies to market, providing new hope for children affected by Batten disease.
https://globalgenes.org/raredaily/tern-therapeutics-launches-with-15-million-and-pipeline-in-cln2-batten-disease/

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE